CRO SERVICES

We are a specialty CRO

We are a specialty CRO

For approximately 20 years, we have supported the development of innovative new drugs, primarily for liver diseases, metabolic disorders, inflammation and fibrosis-related diseases and cancer with the hope that more therapeutics will reach patients faster.

Since our founding, we have focused on efficacy - one of the most critical factors for clinical trial success - and have become a CRO with deep expertise and technical refinement by concentrating on providing drug efficacy evaluation studies using animal models with high clinical relevance to support that success.

SMC Laboratories Inc.

Technoport Kamata Center Bldg. 2-16-1 Minami-Kamata Ota-City Tokyo, 144-0035 Japan
TEL +81-3-6715-9101
https://www.smccro-lab.com/

Proven record

  • 1,500+
    Client

  • 30+
    Country

  • 90%
    Repeat rate

  • 80+
    Publication

  • 90+
    Presentation

Specialty

  • Non-clinical
    In vivo efficacy

    SMC Laboratories provides non-clinical in vivo efficacy studies with a strong focus on clinical relevance.
    By carefully selecting disease models and study designs that reflect human pathology and clinical endpoints, we generate data that directly support decision-making in drug discovery and development, rather than simply demonstrating pharmacological activity.

  • STAMTM model
    Patented model

    Using our proprietary STAMTM mouse model and related disease models, SMC Laboratories has generated extensive efficacy data for leading compounds, including Resmetirom, Semaglutide, and FGF21 agonists.
    These models have been utilized in MASH, fibrosis, and oncology research for many years, and multiple efficacy case studies have been disclosed through publications and scientific presentations.

  • Metabolic disorders
    Liver diseases

    We are specialized in metabolic disorders and liver diseases, with broad experience in clinically relevant in vivo models. Our expertise covers MASH, fatty liver, hepatitis, liver fibrosis and cirrhosis, acute liver failure, and cholangitis (including PBC and PSC), supporting drug efficacy evaluation across a wide range of liver-related indications.

  • Inflammation
    Fibrosis
    Cancer

    We have extensive experience in inflammation-, fibrosis-, and cancer-related diseases, including MASH-HCC, liver cancer, inflammatory bowel disease, systemic sclerosis, psoriasis, pulmonary fibrosis, and chronic kidney disease. In oncology studies, we also support xenograft models with in vivo imaging–based efficacy evaluation using IVIS, enabling quantitative and longitudinal assessment of tumor growth and treatment response.

Sites and Functions

With two bases in California and Japan, we provide high-quality, valuable in vivo drug efficacy testing services to our customers through seamless collaboration between both locations, supporting the acceleration of cutting-edge research and development globally.

  • SMC Group International, Inc.

    Newport Beach, California

    SMC Group International, Inc.

    As an American corporation, we are the primary contact, communicating and executing administrative operations for customers in North America.

  • SMC Laboratories, Inc.

    Tokyo, Japan

    SMC Laboratories, Inc.

    A base equipped with experimental facilities. Operates all the experimental works and studies with a capacity of over 2,000 mice.

Contact us for CRO services

Approved Supplier

Registered on Scientist.com and Science Exchange, we provide non-clinical in vivo pharmacology and efficacy studies.

Scientist.com and Science Exchange are global research outsourcing platforms that connect pharmaceutical and biotechnology companies with qualified CROs and research service providers worldwide.

  • Pharmacology study
    (In vivo drug efficacy testing)

  • Histopathological analysis

  • Biological sample

Our model

We mostly specialized in diseases involving metabolic, inflammation and fibrosis, however, we are also experienced in creating Made-to-Order models based on our customer’s specific needs.

STAMTM model
- our proprietary mouse model -

The world’s first mouse model that induces liver cancer from MASH*

  • ・Utilized in MASH research for over 20 years
  • ・Mimics the progression of human MASH-HCC** with the development of 100% liver cancer
  • ・Suitable for evaluating immunotherapy and molecularly targeted drugs, not only for MASH

*Metabolic Dysfunction-Associated Steatohepatitis

**Hepatocellular Carcinoma

  • LIVER

    • MASH
    • Liver fibrosis/cirrhosis
    • Liver cancer
    • Acute liver failure
    • Cholangitis (PBC, PSC)

  • SKIN

    • Systemic sclerosis
    • Psoriasis

  • LUNG

    • IPF
    • COPD
    • Acute lung injury

  • Colon

    Inflammatory bowel disease

  • KIDNEY

    Chronic kidney disease

  • Other

    • Cancer
    • Arthritis
    • Duchenne muscular dystrophy
    • Alzheimer’s Disease

For more technical information about the models, please visit the SMC Laboratories website.
https://www.smccro-lab.com/

Selected Clients in CRO Business

Pharmaceutical Companies

  • Boehringer Ingelheim International GmbH（Germany）
  • Bristol Myers Squibb Company（United States）
  • Chugai Pharmaceutical Co., Ltd.（Japan）
  • Genentech, Inc.（United States）
  • Merck & Co., Inc.（United States）
  • Novartis AG（Switzerland）
  • Pfizer Inc.（United States）

Biotechnology Companies

  • Abliva AB（Sweden）
  • Allysta Pharmaceuticals, Inc.（United States）
  • AprilBio Co., Ltd.（South Korea）
  • AuraSense Therapeutics, LLC（United States）
  • Autophagy Sciences, Inc.（United States）
  • Axcella Health Inc.（United States）
  • Can-Fite BioPharma Ltd.（Israel）
  • Carmot Therapeutics, Inc.（United States）
  • Cellaïon（France）
  • ChemomAb Ltd.（Israel）
  • CohBar, Inc.（United States）
  • Continuum Biosciences Pty Ltd.（Australia）
  • Cempra Pharmaceuticals, Inc.（United States）
  • Eccogene（China）
  • Enanta Pharmaceuticals, Inc.（United States）
  • Enyo Pharma S.A.（France）
  • Enzychem Lifesciences Corporation（South Korea）
  • Esperion Therapeutics, Inc.（United States）
  • Galectin Therapeutics Inc.（United States）
  • Gemphire Therapeutics, Inc.（United States）
  • GN Corporation Co., Ltd.（Japan）
  • Heel GmbH（Germany）
  • J2H Biotech, Inc.（United States）
  • MRM Health NV（Belgium）
  • Molecure S.A.（Poland）
  • NeuroVive Pharmaceutical AB（Sweden）
  • PharmAkea, Inc.（United States）
  • Pharmaxis Ltd.（Australia）
  • Probiodrug AG（Germany）
  • Promethera Biosciences S.A.（Belgium）
  • Sabinsa Corporation（United States）
  • Stelic Institute & Co., Inc.（Japan）
  • Symic Bio, Inc.（United States）
  • twoXAR, Inc.（United States）
  • VBL Therapeutics Ltd.（Israel）

Academic Institution

  • Chiba University（Japan）
  • Dokkyo Medical University（Japan）
  • Heidelberg University Hospital（Germany）
  • Hyogo Medical University（Japan）
  • Institute of Molecular and Cell Biology（Singapore）
  • Jichi Medical University（Japan）
  • Juntendo University（Japan）
  • Kagoshima University（Japan）
  • Kanazawa Medical University（Japan）
  • Kanazawa University（Japan）
  • Keio University（Japan）
  • Kobe Pharmaceutical University（Japan）
  • Kurume University（Japan）
  • Marshall University Joan C. Edwards School of Medicine（United States）
  • National Cancer Center Hospital East（Japan）
  • National Institute of Health Sciences（Japan）
  • National Defense Medical College（Japan）
  • Okayama University（Japan）
  • Obihiro University of Agriculture and Veterinary Medicine（Japan）
  • Saga University（Japan）
  • The Jikei University School of Medicine（Japan）
  • The University of Hong Kong（Hong Kong）
  • The University of Tokyo（Japan）
  • University of California（United States）
  • University of Hawaii（United States）
  • University of Nebraska（United States）
  • University of Yamanashi（Japan）
  • Virginia Commonwealth University（United States）
  • Yokohama City University（Japan）